Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Soothing Beta Cream is a topical therapeutic formulation containing 0.5% barley-derived beta-glucan, developed by the physician-led brand Dr. Mom in collaboration with the University of Alberta. It is designed as an adjunctive therapy for the treatment of incontinence-associated dermatitis (IAD), a common skin condition in hospitalized adults. The active ingredient, beta-glucan, is a naturally derived polysaccharide that functions by enhancing skin hydration, strengthening the skin barrier, and modulating inflammatory responses. By acting as an agonist for receptors such as Dectin-1 on immune cells, it promotes wound healing and reduces symptoms like itching, pain, and irritation. The cream is hypoallergenic and specifically formulated for sensitive or compromised skin.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Soothing Beta Cream.